Summary
In a single-site, retrospective study comparing the efficacy of several platinum doublet regimens in patients with EGFR wild-type, nonsquamous non–small cell lung cancer, no differences were found in overall survival or response rate between platinum plus pemetrexed or nonpemetrexed therapies (eg, gemcitabine, taxanes).
- retrospective study
- EGFR wild-type
- nonsquamous
- non–small cell lung cancer
- platinum
- pemetrexed
- gemcitabine
- taxanes
- targeted treatment
- oncology clinical trials
- © 2015 SAGE Publications